209 related articles for article (PubMed ID: 35250391)
21. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
22. Imaging Very Late Antigen-4 on MOLT4 Leukemia Tumors with Cysteine Site-Specific
Kim M; Jung KH; Kim JL; Koo HJ; Jung HJ; Lee H; Lee KH
Mol Pharm; 2024 Mar; 21(3):1353-1363. PubMed ID: 38282332
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.
Kang L; Jiang D; Ehlerding EB; Barnhart TE; Ni D; Engle JW; Wang R; Huang P; Xu X; Cai W
Mol Pharm; 2018 Apr; 15(4):1627-1634. PubMed ID: 29537283
[TBL] [Abstract][Full Text] [Related]
24. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
[TBL] [Abstract][Full Text] [Related]
25.
van der Veen EL; Giesen D; Pot-de Jong L; Jorritsma-Smit A; De Vries EGE; Lub-de Hooge MN
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020241
[TBL] [Abstract][Full Text] [Related]
26.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
27. Immuno-PET Imaging of
Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
[TBL] [Abstract][Full Text] [Related]
28. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
29. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of
Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N
J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145
[TBL] [Abstract][Full Text] [Related]
30. In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with
Li M; Ehlerding EB; Jiang D; Barnhart TE; Chen W; Cao T; Engle JW; Cai W
Am J Transl Res; 2020; 12(5):1862-1872. PubMed ID: 32509182
[TBL] [Abstract][Full Text] [Related]
31. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
32. Probody Therapeutic Design of
Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
35. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
36. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive
Peplau E; De Rose F; Reder S; Mittelhäuser M; Scafetta G; Schwaiger M; Weber WA; Bartolazzi A; Skerra A; D'Alessandria C
Thyroid; 2020 Sep; 30(9):1314-1326. PubMed ID: 32200708
[No Abstract] [Full Text] [Related]
37. Differential expression of FAK and Pyk2 in metastatic and non-metastatic EL4 lymphoma cell lines.
Zhang Z; Knoepp SM; Ku H; Sansbury HM; Xie Y; Chahal MS; Tomlinson S; Meier KE
Clin Exp Metastasis; 2011 Aug; 28(6):551-65. PubMed ID: 21533871
[TBL] [Abstract][Full Text] [Related]
38. Spatio-temporal biodistribution of
Sta Maria NS; Khawli LA; Pachipulusu V; Lin SW; Zheng L; Cohrs D; Liu X; Hu P; Epstein AL; Jacobs RE
Sci Rep; 2021 Jul; 11(1):15077. PubMed ID: 34302002
[TBL] [Abstract][Full Text] [Related]
39. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
40. Development of
Kol A; Fan X; Wazynska MA; van Duijnhoven SMJ; Giesen D; Plat A; Van Eenennaam H; Elsinga PH; Nijman HW; de Bruyn M
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]